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The belief that G protein-coupled receptors exist and function as monomeric, non-interacting species has been largely supplanted in recent years
by evidence, derived from a range of approaches, that indicate they can form dimers and/or higher-order oligomeric complexes. Key roles for receptor
homo-dimerisation include effective quality control of protein folding prior to plasma membrane delivery and interactions with hetero-trimeric G
proteins. Growing evidence has also indicated the potential for many co-expressedG protein-coupled receptors to form hetero-dimers/oligomers. The
relevance of this to physiology and function is only beginning to be unravelled but may offer great potential for more selective therapeutic
intervention.
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Protein–protein interactions are integral to the organisational
structure and function of cell signalling networks, and many* Tel.: +44 41 330 5557; fax: +44 41 330 4620.
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doi:10.1016/j.bbamem.2006.09.021classes of receptors and other signal transducing polypeptides
form constitutive or regulated dimers and/or higher order oligo-
mers [1]. In recent years a vast range of studies have demon-
strated the capacity of a large number of G protein-coupled
receptors (GPCRs) to interact to form homo-dimers/oligomers.
Such interactions are important for cell surface delivery, and the
organisational structure of these complexes may also be central
Table 1
Structural domains reported to be involved in GPCR dimerisation/
oligomerisation
Receptor Implicated domains References
Rhodopsin TMD IV (V) [3,14,15]
Dopamine D2 TMD IV [18,19]
α1b-adrenoceptor TMD IV(I, V/VI) [20]
Complement C5a TMD I, II, IV [21]
Bradykinin B2 ECD [22]
Adenosine A2a TMD V [23]
Yeast α factor TMD I, VI [24,25]
β2-adrenoceptor TMD VI [26]
TMD=transmembrane domain. ECD=extracellular domain.
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recently the potential for hetero-dimeric/oligomeric interactions
between co-expressed GPCRs has also been explored exten-
sively and such interactions can result in alterations in ligand
pharmacology, the nature of the signal(s) generated and cellular
trafficking of the complexes. Although a rapidly developing
area, key questions relating to the general importance of GPCR
hetero-dimerisation/oligomerisation in native tissues remain to
be addressed adequately, largely because of the paucity of
selective pharmacological tools and immunological reagents to
identify and modulate the function of such hetero-dimers.
Identification, generation and use of such reagents will be
fundamental in defining if such complexes may be novel targets
that can be exploited for therapeutic intervention.
A large number of recent reviews [2–9] have considered
many of these topics. The current review will hence focus on the
structural organisation of GPCR dimers/oligomers and the
implications of this for function.
2. The structural organisation of rhodopsin
Only for the photon receptor rhodopsin are high resolution, 3
dimensional crystal structures available [10,11]. However, these
static structures of detergent-extracted receptor, although
remarkably informative on the orientation and organisation of
the seven transmembrane helix bundle, provided no insights into
potential quaternary structure. By contrast, both the application
of atomic force microscopy to discs from mouse rod outer
segments [12] and the use of cryo-electron microscopy on 2-
dimensional crystals of squid rhodopsin [13] have shown higher-
order organisation of the proteins. In the pictures obtained by
atomic force microscopy, rhodopsin is organised within para-
crystalline arrays with densely packed, double rows of the
receptor. Using such images as a starting point, and given the
high density of rhodopsin in rod outer segments, models of
potential quaternary structure were generated that optimised
packing arrangements. These models have suggested interac-
tions between rows of dimers to be provided by contacts between
elements of transmembrane domain I, whilst key interactions
between monomers of a dimer are provided by contacts
involving transmembrane domains IV and V [3,14]. Interest-
ingly, the electron density maps derived from the 2-dimensional
crystals of squid rhodopsin provide evidence of a symmetrical
transmembrane domain IV-transmembrane domain IV interac-
tion as a key structural interface [13] and although squid
rhodopsin has relatively low overall sequence identity with
mammalian opsins this may well represent a conserved element
in interactions between rhodopsin-like, family A GPCRs. As
an alternative approach, Kota et al. [15] expressed opsin
heterologously in COS1 cells. Following initial fluorescence
resonance energy transfer (FRET) experiments to confirm
interactions between forms of opsin tagged with either cyan or
yellow fluorescent protein, dimer formation was assessed by the
rate of disulphide bond formation in the presence of cupric
orthophenanthroline, using opsin mutants in which a range of
specific amino acids were mutated to cysteine. These studies
showed most rapid dimer formation with the mutants W175C(transmembrane domain IV) and Y206C (transmembrane
domain V) [15] consistent with key roles of these regions in
quaternary structure.
3. The structural organisation of other class A GPCRs
High level expression of rhodopsin in rod outer segments has
resulted in the capacity to purify substantial amounts of this
receptor and to apply biophysical approaches to understand its
organisation and function that have not generally been practical
for other GPCRs. However, significant progress has recently
been made in understanding the structural organisation of a
number of other GPCRs (Table 1). The dopamine D2 receptor is
a case in point. Employing cysteine cross-linking studies and
forms of the D2 receptor in which amino acids of transmembrane
domain IV that point away from the ligand binding pocket,
defined as the water accessible core within the transmembrane
helices, were mutated, Guo et al. [16] were initially able to
demonstrate cross-linking of a D2 receptor containing Cys at
position 168 near the top of transmembrane domain IV (4.58 in
the Ballesteros and Weinstein [17] numbering system). Such
cross-linking did not occur when this residue was mutated. Guo
et al. [18] followed up this initial study with a more
comprehensive cross-linking scan over 23 amino acids of
transmembrane domain IV. Cross-linking interactions were
shown to occur when cysteine residues were placed along two
contiguous faces of this helix and the rate of cross-linking of
residues in these faces was differentially altered in the presence
of agonist and inverse agonist ligands, consistent with the
concept that alterations at the homo-dimer interface might be
important in the generation of active and inactive states of this
receptor. Interestingly, cross-linking via amino acids 4.50, 4.54,
and the previously studied 4.58, resulted in constitutive capacity
of the receptor to promote [35S]GTPγS binding, suggesting that
effective alignment of this interface between pairs of D2
receptors might be an important task for ligands that display
agonism [18]. Earlier studies [19] examining interactions
between fragments of the D2 receptor had also provided
evidence for dimerisation involving transmembrane domain IV
based, in part, on self-association of fragments of the receptor
containing this element. Interestingly, however, the studies of
Lee et al. [19] suggested that the transmembrane domain IV
interface might only be one element responsible for dimeric/
oligomeric organisation of the D2 receptor and Guo et al. [18]
Table 2
Proposed roles of GPCR dimerisation/oligomerisation
Role of dimerisation/
oligomerisation
Receptor(s) References
Protein folding β2-adrenoceptor [34]
CXCR1 [35]
α2-adrenoceptors [36]
TSH receptor [38]
Frizzled 4 [39]
Calcium sensing receptor [40]
Melacortin-1 receptor [41]
CXCR1–CXCR2
hetero-dimer
[35]
Efficient signal
transduction
Rhodopsin [3,14]
BLT1 leukotriene
B4 receptor
[53]
G-protein selectivity
(hetero-dimers)
MOP and DOP receptors [76,77]
D1 and D2 dopamine
receptors
[78,79]
Signal alteration/
modulation
(hetero-dimers)
Orexin-1 receptor and
cannabinoid CB1
[80]
Melatonin MT1 and GPR50 [81]
MrgD and MrgE [82]
DOP receptor and SNSR-4 [83]
Somatostatin sst2a and sst3 [87]
Control of
physiological
function
(heterodimers)
DOP and KOP receptors [95]
Angiotensin AT1 and
Bradykinin B2
[97–99]
Angiotensin AT1 and Mas [100,101]
EP1 prostanoid receptor and
β2-adrenoceptor
[102]
Various adenosine and
dopamine receptors
[104–107]
Adenosine A1 and A2A [108]
Dopamine D2 and
cannabinoid CB1?
[110]
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exchange’ model for receptor activation that would require the
organisational structure being at least a tetramer, if not a yet more
complex structure.
Evidence for a role of transmembrane domain IV as a dimer
interface, and of higher order organisation, is not restricted to
the D2 receptor. Carrillo et al. [20] indicated a key role for
transmembrane domain IV in the α1b-adrenoceptor based on
symmetrical interactions between receptor fragments containing
this sequence. Furthermore, as similar studies also indicated a
symmetrical interface to be provided by transmembrane domain
I, Carrillo et al. [20] proposed a ‘daisy chain’ organisation that
could generate rows of monomers. Non-symmetrical interac-
tions involving transmembrane domains I and/or II with
transmembrane domains V and/or VI, or conceivably elements
of intracellular loop I that connects transmembrane domains I
and II with intracellular loop III, that connects transmembrane
domains V and VI, were then suggested to align the ‘rows of
monomers’. The cysteine cross-linking approach has also been
used to suggest roles for elements of transmembrane helices I
and II or IV in the quaternary structure of the complement C5a
receptor [21]. Here again, the data were most easy to interpret as
allowing oligomeric organisation rather than interactions being
restricted to dimers. Although transmembrane domain IV has
been a focus of attention in the studies noted above, a variety of
other elements of the primary sequences of rhodopsin-like
GPCRs have been suggested to be important in generating
quaternary interactions. These include contributions of sialyla-
tion and N-glycosylation at the extracellular face of the
bradykinin B2 receptor [22], potentially of transmembrane
domain V in the adenosine A2a receptor [23], transmembrane
domain I and the N-terminal domain of the yeast α factor
receptor [24,25] and transmembrane domain VI of the β2-
adrenoceptor [26]. As well as direct experimental studies a
range of computational approaches have also been applied to
attempt to predict potential dimerisation interfaces within the
helical bundles of rhodopsin-like GPCRs [27–31]. These have
provided information that is, in general, in relatively good
agreement with experimental observations. However, whether
this is because of, or in spite of, the limited experimental data set
is unclear. One extremely interesting and provocative prediction
from the analyses of both Nemoto and Toh [29] and Filizola and
Weinstein [30] is that the homo-dimerisation interfaces of even
closely related GPCRs that respond to similar ligands may be
markedly distinct. If this is confirmed by direct experiments it
will provide interesting challenges in prediction and determina-
tion of hetero-dimer interfaces but may suggest means to
selectively target and disrupt GPCR homo- and hetero-dimers,
and hence may perhaps have therapeutic implications. To date,
however, there have been no detailed experimental studies to
define the molecular basis of hetero-dimeric interactions.
Furthermore, some analyses suggest the potential for function-
ally important residues on the external face of each transmem-
brane helix of a GPCR [31], potentially consistent with the
organisation of GPCRs into larger multimeric complexes. Each
of the above noted computational studies focused on the
formation of ‘contact’ dimers. Earlier computational analyseshad suggested the potential for the existence of so called ‘domain-
swap’ dimers [32], in which elements of each protomer were
interchanged within the dimer. Although there is currently little
experimental support for domain-swap dimers being common-
place, in the case of the histamine H1 receptor Bakker et al. [33]
have provided evidence that such forms do exist. Defined point
mutations in either transmembrane helix III (Asp107Ala) or
transmembrane helix VI (Phe432Ala) eliminate binding of the
antagonist [3H] mepyramine. However, [3H]mepyramine binding
sites with the expected pharmacology of the histamine H1
receptor were generated when the Asp107Ala and Phe432Ala
mutants were co-expressed. Although the number of [3H]
mepyramine binding sites generated via this approach were low
compared to when the wild type receptor was expressed, such
results are consistent with the potential for contact dimers and
domain-swap dimers to both form and co-exist [33].
4. Formation of dimers/oligomers is an early step in GPCR
maturation and cell surface delivery
A substantial literature has provided evidence for GPCR
dimerisation occurring at the level of synthesis in the
endoplasmic reticulum or during protein maturation in the
Golgi apparatus [9] (Table 2). Introduction of endoplasmic
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cell surface delivery of the modified receptor but can also hinder
cell surface delivery of a co-expressed, unmodified receptor.
Replacement of the C-terminal tail of the β2-adrenoceptor with
the equivalent region of the GABAb-R1 subunit, which contains
a well-characterised arginine-based endoplasmic reticulum
retention signal, resulted in the modified β2-adrenoceptor
being trapped in the endoplasmic reticulum of transfected cells
[34]. This construct also limited cell surface delivery of co-
expressed wild type β2-adrenoceptor [34]. As cell surface
delivery of wild type β2-adrenoceptor was not compromised by
co-expression of the wild type GABAb-R1, that is also retained
in the endoplasmic reticulum but does not interact with the β2-
adrenoceptor [34], such studies are indicative of protein–protein
interactions between the two forms of the β2-adrenoceptor with
the mutant acting as a dominant negative. The C-terminal 14
amino acids of the α2C-adrenoceptor also contain an endoplas-
mic reticulum retention motif. Addition of this sequence to the
C-terminal tail of the chemokine CXCR1 receptor produced a
form of this GPCR that was entirely limited to the endoplasmic
reticulum [35]. Co-expression of the intracellularly-retained
form of CXCR1 with wild type forms of either CXCR1 or the
closely related GPCR CXCR2 resulted in marked reduction in
their cell surface delivery [35], whereas cell surface delivery of
the α1A-adrenoceptor, which was shown by a range of
approaches to be unable to interact with CXCR1 with high
affinity, was unaffected [35].
As well as introduction of endoplasmic reticulum retention
motifs into GPCRs lacking such sequences, mutations in a
variety of positions can eliminate or limit cell surface trafficking
of a receptor and the mutants may act as dominant negatives for
cell surface delivery of wild type receptors. Such a strategy has
recently been employed to examine interactions amongst α2-
adrenoceptor subtypes [36] and a regulated secretion/aggrega-
tion technology was employed by Hansen et al. [37] to explore
aspects of dimerisation and function of the angiotensin II AT1
receptor. An F(6X)LL motif, common in the proximal C-
terminal tail of a number of rhodopsin-like GPCRs, has been
suggested to be key in regulating endoplasmic reticulum to cell
surface delivery [36]. However, as this region is the central core
of the region often described as the ‘4th intracellular loop’ or
‘helix 8’, based on similarity of sequence with the equivalent
region of bovine rhodopsin, it is likely that mutation in this
region will have global effects on receptor folding and function
and that it is not simply a motif that is key to release from the
endoplasmic reticulum.
Naturally occurring mutations in GPCRs are also known to
limit GPCR cell surface delivery. For example, various
mutations in the thyroid stimulating hormone receptor are
known to result in aberrant cell surface expression and can exert
dominant negative effects on cell surface delivery of the wild
type receptor by forming a complex at the level of the
endoplasmic reticulum [38]. This can potentially explain
abnormal endocrine phenotypes in patients who are hetero-
zygous for the mutation [38]. Similar molecular interactions
appear to underlie effects of a mutant of the Frizzled 4 seven
transmembrane domain receptor that is associated with familialexudative vitreoretinopathy [39], where co-expression with wild
type Frizzled 4 shows that the mutant form dimerises with wild-
type Fz4, retains it in the endoplasmic reticulum and inhibits its
signalling [39]. Equivalent observations have been made for a
series of other receptors, including the calcium-sensing receptor
[40] and the melacortin-1 receptor [41], where interactions
between wild type and dominant negative mutants of the
receptor may contribute to hair colour [41,42]. This general
concept has recently developed into a specific sub-area of GPCR
homo-dimerisation studies with both substantial support via
basic studies, and with clear implications for disease [43,44]. A
number of, but not all, endoplasmic reticulum-retained GPCR
mutants can be ‘rescued’ by treatment of cells expressing these
mutants with so-called chemical or pharmacological chaperones
[45–47], and there are potential therapeutic implications of this
general approach that stretch well beyond diseases associated
with endoplasmic reticulum-retained GPCR mutants [47]. To
date, studies on endoplasmic reticulum retention of GPCRs and
disease have been limited to homo-dimeric interactions.
However, given the level of interest in GPCR hetero-dimeric
interactions (see later) it would not be surprising if a mutant
GPCR that is retained in the endoplasmic reticulum might limit
cell surface delivery of a second co-expressed wild type GPCR
and limit its function.
Although clearly vital, GPCR homo-dimerisation is not
simply a strategy to ensure proper folding, maturation and cell
surface delivery of GPCRs. Although even for rhodopsin,
isolated monomers can be shown to be functional [48],
monomers appear to have lower signal generation capacity
than dimers/oligomers [49]. Based on the molecular dimensions
of rhodopsin and its associated G protein transducin, models in
which a rhodopsin dimer straddle or provide an appropriate
footprint to bind a single transducin α,β/γ subunit hetero-trimer
effectively have been proposed [3,14]. This would appear to
provide an attractive model for efficient signal transduction
requiring receptor dimerisation (Table 2), or indeed, higher
order oligomerisation, to provide effective signal amplification
via a relay system because measurements of the number of
transducins that can be activated by a single photon of light [50]
appear difficult to comprehend within a simple 1:1 organisation
of rhodopsin dimer and transducin hetero-trimer. Indeed, early
studies did suggest the potential of oligomeric organisation of G
proteins in brain membranes [51,52]. Recent biophysical
studies on recombinantly expressed receptors reconstituted
with purified G proteins have also supported the idea of the
basic unit of signal transduction of the BLT1 leukotriene B4
receptor as a pentamer containing two receptors and the three
subunits of a G protein hetero-trimer [53]. Although less direct,
studies on the 5-HT2C receptor [54], the α1b-adrenoceptor [55]
and the DOP opioid receptor [56] are each consistent with this
model.
Theoretically, mutations or small molecules that prevent
dimerisation might be expected to limit GPCR-mediated signal
transduction. However, such effects may be difficult to separate
from unfolding and incomplete receptor maturation. Equally, if
dimerisation interfaces are quite extensive then minor mutation
might be insufficient to ablate protein–protein interactions.
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interactions for certain chemokine receptors do not limit cell
surface delivery [57] and this appears inconsistent with the
simple models delineated above. Also difficult to incorporate
into a ‘one-size fits all’ model of dimerisation/oligomerisation
in the endoplasmic reticulum/Golgi being vital for cell surface
delivery are reports of agonist ligands either promoting, or
being required for, GPCR dimerisation [58,59]. In studies that
rely exclusively on resonance energy transfer techniques
[60,61] relatively small alterations in receptor conformation
may alter the observed signal and be interpreted as a agonist-
induced alteration in dimeric/oligomeric status. However, if
increases or decreases in signal are produced by both agonists
and antagonist ligands this may suggest that the effect measured
is not related to alterations in overall quaternary structure
[62,63]. A series of other studies have indicated the potential for
agonist ligands to cause dissociation of certain pre-formed
GPCR dimers/oligomers [64,65]. Although subject to the same
caveats as increases of resonance energy transfer signal, it is
unclear if, or how, dissociated dimers would re-associate during
the processes of receptor internalisation and recycling to the cell
surface as there is evidence for the internalisation of receptor-
homo-dimers in response to binding of agonist ligands [66].
Although there have been suggestions that GPCR dimerisa-
tion/oligomerisation might be promoted at relatively high
receptor expression levels and hence potentially be at least
partially an artefact of over-expression, studies on the extent of
β-adrenoceptor dimerisation have indicated that this is
unaltered over a wide range of expression levels [67] whilst
CCR5 receptor dimerisation/oligomerisation occurs at rela-
tively low, physiologically relevant, levels of expression [68].
Although many GPCRs are indeed expressed in relatively low
levels, in many cases the heterogeneity of physiological tissue
used to measure expression levels probably results in a marked
under-estimate of expression levels in individual cells that
actually express the GPCR of interest and hence true measures
of the level of expression of various GPCRs in, for example,
specific neurones remain undefined. Furthermore, although data
indicate that GPCRs such as the neurokinin NK1 receptor exist
as monomers [69] this is not generally consistent with evidence
that information transfer reflecting ligand binding to one
protomer may be communicated to the G protein by altering
the orientation of the dimer interface and transfer of information
via the partner protomer [18].
5. GPCR hetero-dimerisation/oligomerisation
Given the extensive literature on the existence and relevance
of GPCR homo-dimers/oligomers and the importance of
GPCRs as the targets of small molecule therapeutics it is hardly
surprising that the potential existence and relevance of GPCR
hetero-dimers/oligomers has been actively studied. With more
than 400 genes encoding non-sensory GPCRs in the human [70]
and other mammalian genomes co-expression of a number of
these in individual cells is to be expected. Efforts to assess the
relative interaction affinities of closely related GPCRs to form
hetero-dimers/oligomers versus homo-dimers/oligomers havebeen based largely on ‘saturation’ resonance energy transfer
experiments [60]. Such studies have indicated that, for example,
the β1-adrenoceptor and β2-adrenoceptors [67], the CXCR1
and CXCR2 chemokine receptors [35], DOP, KOP and MOP
opioid receptors [71] and various subtypes of muscarinic
acetylcholine receptors [72] generate hetero-dimers with
similar, or only slightly lower, affinity that the corresponding
homo-dimers. For each of the examples noted above there is
clear evidence of the co-expression of the GPCR pairs in native
cells and, as such, unless there are temporal or other means to
limit the co-translation of mRNA into protein it is likely that
these hetero-dimers/oligomers are indeed generated in native
tissues. Although it has been suggested that opioid receptor
hetero-dimers might only form following cell surface delivery,
and in a G protein-dependent manner [73], other studies of these
receptors [71] have supported the general model of dimer/
oligomer formation occurring during receptor synthesis and
maturation. Early studies on the relative interaction affinity of
GPCRs to generate homo- versus hetero-interactions [74]
concluded that hetero-oligomers between closely related
GPCRs subtypes would form more efficiently than between
less closely related GPCRs. Whilst intellectually appealing,
particularly if the basic dimer/oligomer interface(s) is the same
for different class A GPCRs, computational modelling studies
that favour different interfaces even for homo-dimers of closely
related receptors [30] suggest that such a simple view requires
rigorous analysis across a wide range of receptors. Indeed, there
are examples in which the relative propensity of two receptors
to form the hetero-dimer appears to be greater than for the
corresponding homo-dimers [75].
6. Functional consequences of hetero-dimerisation
In recent years a very large number of studies [see [2,4–7,9]
for review] have attempted to explore functional sequelae of
GPCR hetero-dimerisation. In many cases such studies have
employed pairs of GPCRs that are likely to be co-expressed in
physiological settings, but in a number of published studies this
does not appear to have been a priority in the experimental
design. Prior to considering some of the observations reported,
and the implications thereof, it is important to remember that not
all cases in which co-expression of two GPCRs modulates the
function of one or both are likely to reflect or require hetero-
dimerisation. For example, heterologous desensitisation can
profoundly alter receptor function.
Despite such caveats, effects of hetero-dimerisation on signal
identity, ligand pharmacology and receptor trafficking have all
been described. One issue is that unless the hetero-dimer forms
much more efficiently that the corresponding homo-dimers, co-
expression of two GPCRs must be anticipated to result in the
presence of both homo-dimers and hetero-dimers and, although
some suggestions have been examined, strategies to resolve
signals produced by homo- and hetero-dimers in the same cells
are generally limited [2]. Despite these issues, a number of clear
differences in the function and pharmacology of co-expressed
pairs of GPCRs have been reported and attributed to the
generation of GPCR hetero-dimer/oligomer complexes. Again,
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protein–protein interactions rather than indirect effects pro-
duced via downstream signalling and feedback control.
7. GPCR hetero-dimerisation and signal generation
As noted earlier, current views on the physical organisation
of GPCRs and associated G proteins favour a model in which a
GPCR dimer provides a footprint suitable to bind a single G
protein α,β,γ hetero-trimer [3,53,54]. A GPCR hetero-dimer
could then offer a docking interface with differing G protein
selectivity than the corresponding GPCR homo-dimers (Table
2). A range of studies has reported data that are at least
consistent with such a model. Although both MOP and DOP
receptors are generally considered highly selective for activa-
tion of pertussis toxin-sensitive hetero-trimeric G proteins,
when co-expressed, George et al. [76] have reported that signals
insensitive to pertussis toxin treatment were generated. Inter-
estingly, this has been demonstrated to reflect a switch in
coupling such that Gz becomes activated by opioid agonists [77]
and that the distal C-terminal tail of each receptor plays a role in
this switch [77]. In a similar vein, co-stimulation of co-
expressed dopamine D1 and D2 receptors, which a range of
approaches have confirmed to have the ability to form hetero-
dimers [78], results in generation of a phospholipase C-
mediated Ca2+ signal [79], although the D1 receptor is usually
associated with stimulation, and the D2 receptor with inhibition,
of adenylyl cyclase. Perhaps even more interesting in relation to
drug discovery is that co-expression of pairs of GPCRs can alter
the potency and/or ability of receptor agonists to generate
signals. For example, co-expression of the orexin-1 receptor
with the cannabinoid CB1 receptor has been reported to
enhance the potency of the peptide orexin-A to stimulate
phosphorylation of the ERK1 and 2 MAP kinases 100 fold, an
effect that was blocked by the CB1 receptor antagonist/inverse
agonist rimonabant [80]. The concept that hetero-interactions
between GPCRs might alter the potency of action of natural
agonists and that this may be modulated by synthetic ligands
that have no direct affinity for that GPCR when tested in
isolation but may affect a hetero-dimer/oligomer containing the
receptor is clearly of great interest and, if widely applicable, will
require reconsideration of ligand screening approaches [2]. An
interesting extension to this has recently been reported for
interactions between the MT1 melatonin receptor and the
orphan receptor GPR50 [81]. When co-expressed, the presence
of GPR50 is reported to abolish the binding of melatonin to the
MT1 receptor and a key contribution to this effect is provided by
the long intracellular tail of GPR50. Most interestingly, both
GPR50 and the MT1 receptor are expressed endogenously in
hCMEC/D3 endothelial cerebral cells. siRNA-mediated knock-
down of GPR50 levels increased levels of [125I]melatonin
binding [81], consistent with the concept that GPR50/MT1
hetero-dimerisation prevents binding of the ligand. This is not
the only example in which a currently orphan GPCR is able to
modulate the function or potency of a ligand at a second co-
expressed receptor. The mas-related gene (Mrg) receptors are
largely if not exclusively expressed in sensory dorsal rootganglia. Milasta et al. [82] employed cells in which the orphan
GPCR MrgE was expressed constitutively whilst the related
GPCR MrgD, that is known to be activated by β-alanine, was
expressed from a single, defined inducible locus in a time- and
inducer-concentration-dependent manner. As anticipated,
MrgE-MrgD hetero-dimers/oligomers were only produced
subsequent to induction of MrgD expression and the amount
of hetero-dimer present reflected the level of MrgD expression.
Functional potency of β-alanine was enhanced by the presence
of MrgE, potentially because the hetero-dimer was maintained
at the cell surface rather than becoming internalised in response
to the MrgD agonist [82]. Of equal interest is the concept that a
hetero-dimer comprising two co-expressed GPCRs may share a
common ligand. As well as the Mrg receptors (which are also
called sensory neuron-specific G protein-coupled receptors
(SNSRs) in some studies), dorsal root ganglia express the DOP
opioid receptor. Bovine adrenal-medulla-peptide-22 is reported
to be an agonist at both the DOP receptor and the sensory
neuron-specific G protein-coupled receptor-4 (SNSR-4) but the
relevant pharmacophores are distinct. When the two GPCRs
were co-expressed in HEK293 cells bovine adrenal–medulla–
peptide-22-mediated inhibition of adenylyl cyclase (the DOP
receptor signal) was lost whilst stimulation of phospholipase C
(the SNSR-4 signal) was retained [83]. Furthermore, co-
addition of selective DOP and SNSR-4 agonists promoted
SNSR-4 but not DOP signalling, indicating that in the DOP/
SNSR-4 hetero-dimer, DOP receptor ligand binding and/or
function may be masked. Although indirect, the size of bovine
adrenal–medulla–peptide-22 may allow this ligand to bind to
both elements of the hetero-dimer concurrently and there is
evidence that synthetic, designed bivalent ligands that incorpo-
rate distinct pharmacophores at either end of the molecule may
be able to modulate the function of hetero-dimers of opioid
receptor subtypes [84,85]. Significant efforts in medicinal
chemistry are now targeting the concept of generating
molecules that may allow study of GPCR dimers [86]. In a
similar fashion, hetero-dimerisation between somatostatin sst2a
and somatostatin sst3 receptors has been reported to eliminate
binding of a somatostatin sst3 receptor selective agonist [87].
One of the issues frequently raised in relation to efforts to
study the pharmacology and function of GPCR hetero-dimers is
that either transient or stable expression of two GPCRs is likely
to result in the production of homo-dimers as well as potential
hetero-dimers. One approach to address this issue for closely
related GPCRs that display similar affinity to generate homo-
and hetero-interactions is to express one of the pair to
substantially higher levels than the other. It would then be
reasonable to assume that the bulk of the less highly expressed
GPCR would be present within hetero-dimers [88]. Assuming
ligands with good affinity and high selectivity for the less highly
expressed GPCR are available, comparisons of their affinity,
function and structure–activity relationships in cells co-
expressing the two GPCRs with those that express this receptor
alone and at similar total levels may offer insights. As a variant
of this, the expression of one of the potential partners can be
controlled via an inducible promoter to regulate the extent of
hetero-dimerisation. Milasta et al. [82] employed this strategy
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approach is likely to become much more widely employed. A
rather unusual approach to ensure production only of GPCR
‘hetero-dimers’ is to express both from a single open reading
frame [89]. Given the 7 transmembrane domain organisation of
GPCRs, this required insertion of an extra transmembrane
domain between transmembrane helix VII of the first receptor
and transmembrane helix I of the second. The results obtained
with a construct in which the adenosine A2A receptor and the
long isoform of the dopamine D2 receptor were linked together
in this way are rather difficult to interpret, not least because the
measures of ligand binding capacity of the two elements were
very different. However, although other studies in which hetero-
dimerisation has been reported to alter the characteristics of
ligand binding have focused on agonists [81,90,91], and where
the effect may be related to alterations in G protein coupling, it
is at least conceptually possible that antagonist binding capacity
and/or affinity might also be modulated by hetero-dimerisation.
8. GPCR hetero-dimers as physiologically relevant
molecular species
Studies on GPCR hetero-dimerisation performed in trans-
fected cell lines require support from physiological systems
before becoming real therapeutic targets (Table 2). The opioid
receptors have contributed significantly to the development of
thinking in this area and it has been suggested than DOP-MOP
hetero-dimers may be of particular relevance in improving
morphine-based analgesia by limiting tolerance and dependence
[92–94]. Equally, the recent claim that 6′-guanidinonaltrindole
is both a spinally selective analgesic and a DOP-KOP hetero-
dimer selective agonist [95] has provided support for the
physiological expression of opioid receptor hetero-dimers.
The physiological function of receptors for angiotensin II also
appears to be controlled via hetero-dimerisation. Interaction
partners have included the bradykinin B2 receptor and the mas
proto-oncogene [96–100]. Abidar et al. [101] have recently
employed confocal fluorescence resonance energy transfer to
indicate that the angiotensin II AT2 receptor and bradykinin B2
receptor are in close proximity in PC12W cell membranes and
have suggested that influencing their dimerisation, might offer a
potential therapeutic strategy for the treatment of hypertension
and other cardiovascular and renal disorders. Equally, interac-
tions between the angiotensin II AT1 receptor and the bradykinin
B2 receptor have been reported in renal mesangial cells isolated
from spontaneously hypertensive rats and in higher levels
compared with cells from normotensive controls [97]. These
authors also suggest that this hetero-dimer may contribute to
angiotensin II hyper-responsiveness of mesangial cells in
experimental hypertension [97]. It has also been suggested that
levels of this hetero-dimer are increased in pre-eclampsia [98,99]
and display increased sensitivity toward angiotensin II. Altera-
tion of function associated with receptor hetero-dimerisation can
also be productively studied in knock-out animals. Elimination
of the Mas proto-oncogene results in enhanced contraction of
mesenteric microvessels to angiotensin II but not to endothelin
[100]. This is consistent with an observed Mas-AT1 receptorhetero-dimer interaction limiting the function and/or binding of
angiotensin II. However, as noted earlier, hetero-dimerisation
may not be the only contributing factor to such an effect. The
Mas proto-oncogene displays high levels of agonist-indepen-
dent, constitutive activity [101] and activation of protein kinase
C via such constitutive activity can desensitise the AT1 receptor.
Thus, reduced desensitisation of the AT1 receptor in the absence
of Mas is also consistent with the enhanced function of
angiotensin II, without a need to invoke hetero-dimerisation as
a regulatory mechanism.
Increasing evidence is also beginning to provide evidence
that GPCR hetero-dimerisation may be relevant to airway
function and sensitivity and to inflammatory responses.
McGraw et al. [102] have recently provided evidence for the
presence of an EP1 prostanoid receptor/β2-adrenoceptor hetero-
dimer in which the β2-adrenoceptor is poorly coupled to
elevation of cAMP levels and hence to bronchial relaxation. The
authors suggest that such a mechanism may contribute to beta-
agonist resistance found in asthma [102]. Similarly, interactions
between the chemokine CXCR1 receptor and a number of
GPCRs that respond to lysophosphatidic acid or sphingosine 1-
phosphate have been observed [103] and variation in expression
levels of these receptors in individuals may be relevant to the
extent of interleukin 8-mediated white cell chemotaxis.
The other key area of relevance of class A GPCR hetero-
dimerisation for in vivo function has developed from long term
understanding of the interplay between receptors for adenosine
and dopamine. A substantial literature, covering basic biochem-
ical studies to more clinically relevant systems has been
produced and reviewed [104–107]. Furthermore, hetero-dimeric
interactions between the adenosine A1 and A2A receptors have
recently been reported to play a key role in pre-synaptic control
of striatal glutamatergic neurotransmission [108]. Equally,
although more direct experiments on their existence and
relevance in the CNS need to be performed, interactions
between the cannabinoid CB1 receptor and both the D2
dopamine receptor [109] and the MOP opioid receptor [110]
are certainly of great interest and may be of physiological
relevance, particularly as CB1 receptor knock-out animals
display reduced ethanol-induced conditioned place preference
and increased levels of striatal dopamine D2 receptors [111],
whilst D2 dopamine receptors modulate the G protein coupling
profile of the cannabinoid CB1 receptor [112]. Although it is
clearly far more challenging to confirm GPCR hetero-interac-
tions in physiologically relevant cells and tissues, detailed
analysis of the function and pharmacology of GPCRs in cells
and tissues of ‘knock-out’ animals, and particularly conditional
knock-outs, as well as the reconstitution of function and
pharmacology by introduction of potential hetero-dimer/oligo-
mer pairs into cells from knock-out animals [113] is likely to
provide useful information.
9. Modulating GPCR hetero-dimer function
Both to understand the functional significance of GPCR
hetero-dimers in vivo and to explore their potential as selective
therapeutic targets requires the identification of hetero-dimer
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selectively disrupt hetero-dimer pairs. As noted earlier, there is a
significant, long standing literature on this concept of synthesis-
ing hetero-dimer selective ligands, not least in relation to the
medicinal chemistry of opioid receptor ligands. Indeed, a recent
study on molecules in which distinct KOP and DOP pharma-
cophores were linked via spacer arms have indicated certain of
these molecules to display substantially higher affinity in cells
co-expressing the two GPCRs than in mixtures of cells
expressing each individually [84]. Molecules of this nature are
unlikely to represent a starting point for molecules that can be
employed therapeutically but may be very useful tools to aid
understanding. It was thus a considerable surprise when 6′-
guanidinonaltrindole, a relative simply analogue of a well
known KOP receptor ligand, was recently described as a DOP-
KOP hetero-dimer selective agonist [95]. Furthermore, its
efficacy as a spinally-selective analgesic resulted in the
conclusion that DOP-KOP hetero-dimers may be expressed in
spinal cord but not in brain [95]. There is no doubt that this
publication has both raised awareness of the therapeutic
potential of targeting GPCR hetero-dimers [114] and raised
expectation that a range of such ligands will be identified via
appropriate screening strategies. Other ligands certainly show
indications of GPCR hetero-dimer selectivity. For example,
although studied in a somewhat artificial manner, a number of
anti-parkinsonian compounds appear to have high agonist
affinity at the dopamine D2/D3 receptor hetero-dimer [115]. It
is certainly possible that many ligands, including those studied
previously, will unexpectedly show either substantial hetero-
dimer selectivity or will modulate hetero-dimer function in
animal studies and clinical settings despite never have been
screened for such effects. Of course, strategies other than the use
of conventional small molecule antagonists may potentially be
useful to disrupt both GPCR homo- and hetero-dimers/
oligomers and hence limit function. In one of the earliest
detailed studies of GPCR homo-dimerisation, a peptide corres-
ponding to transmembrane domain VI of the β2-adrenoceptor
was shown to disrupt both protein–protein interactions and
signal generation [116]. Equally, although the mechanism is
entirely unclear, infusion of peptides corresponding to trans-
membrane domain VII of a number of GPCRs into animals has
been reported to interfere selectively with GPCR function [117].
Pepducins are cell penetrating peptides incorporating sequences
from GPCRs and have been shown to have potential as
therapeutic agents [118,119]. Although the targeting of
protein–protein interaction interfaces has attracted limited
interest in the drug discovery industry, if it emerges that
GPCR homo-dimers and hetero-dimers interact via different
sequence elements, then such an approach may certainly be
worthy of consideration. The protease activated receptors, PAR1
and PAR4, associate as a hetero-dimeric complex in human
platelets and a combination of small-molecule antagonists and
pepducins has recently been described as being effective in
treating carotid artery occlusion [120]. Further studies in this
area are likely to also contribute to a greater understanding of the
existence and relevance of GPCR hetero-dimers in the selective
regulation of physiological processes. Given the importance ofGPCRs as therapeutic targets [121] this may offer a means for
enhanced selectivity in the use of GPCR ligands as medicines.
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